2 not yet recruiting, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Not yet recruiting 2, Completed 1 |
Follow Surgical Site Infection (SSI): new trials by email Literature Review of Surgical Site Infection (SSI) trials Research Report on Surgical Site Infection (SSI)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation: NGS diagnostic findings - Next Generation Sequencing (NGS), Surgical Site Infection (SSI) | Phase 3 | Not yet recruiting | Johns Hopkins Bloomberg School of Public Health | 250 | 2027-01-01 | 2026-11-05 |
| Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority Study of Placebo vs Cefazolin Cefazolin 2 g Infusion, Placebo infusion of .9 normal saline - Breast Cancer, Breast Surgery | Phase 3 | Not yet recruiting | University Hospital, Clermont-Ferrand | 1600 | 2026-11-01 | 2026-10-27 |
| Efficacy of Intrawound Vancomycin in Spine Surgery vancomycin, Standard surgical closure - Surgical Site Infection (SSI), Spine Diseases | Phase 3 | Completed | Ain Shams University | 416 | 2023-12-02 | 2026-10-15 |
Surgical Wound Infection (3) · Breast Neoplasms (1) · Spinal Diseases (1)
Infections (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Postoperative Complications (3) · Wound Infection (3) · Bone Diseases (1) · Breast Diseases (1) · Musculoskeletal Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Cefazolin (1) · Vancomycin (1)
Ain Shams University (1) · Johns Hopkins Bloomberg School of Public Health (1) · University Hospital, Clermont-Ferrand (1)
Egypt (1) · France (1) · United States (1)
Marc Garnier, MD, PhD (1) · Roman M Natoli, MD (1)
2025 (1)